GlobeNewswire

Striving for Gold - Laying the Groundwork for the Olympic Healthcare Interoperability Initiative

Dela

LAS VEGAS, Nev., March 06, 2018 (GLOBE NEWSWIRE) -- The spirit of health and well-being is core to the founding principles of the Olympic Games and heralds the tenets of sustainable social development within each host and participating country. With the ambitious goal of integrating advanced digital health information sharing into health services provided before, during, and after the Games, the Olympic Healthcare Interoperability (OHI) Initiative & OHI Foundation have been formed to aggressively pursue this vision.

OHI, a digital health industry initiative with charter sponsorship from not-for-profit organizations HIMSS and SNOMED International, was created to advance the seamless exchange and use of health information globally through the Olympic Games. Starting with the 2020 Summer Games in Tokyo, OHI's goal is to "showcase the possible" and "implement the real", through the communication of digital health information, for the benefit of the 1,000's of athletes, trainers and staff, volunteers and attendees. With each edition of the Games, a digital health legacy will be crafted to establish a comprehensive, world-wide infrastructure supportive of appropriate access to relevant clinical information...anywhere, at any time.

Utilizing the latest innovations in digital health, OHI will connect pre-Games, person-specific healthcare information with information generated at the Games by Olympic and Host City healthcare service providers, which will flow back around the world with each individual once the Games conclude. OHI's initial scope will include patient identity matching and access to international patient summaries with capacity to include the significant facets of a patient's digital health record over time.  All with the needed security, privacy and consent framework that will ensure appropriate access to all information.

Consider the case of a Jamaican athlete collapsing on the track, showing symptoms of cardiac stress.  Medical personnel at the stadium use an electronic medical record (EMR) system to query the athlete's electronic records from Jamaica, and discover a number of allergies, current medications, and medical conditions to inform a treatment plan. The athlete, requiring a surgical procedure and transferred to the host city's tertiary hospital, is followed by the necessary diagnostic and treatment information via OHI interoperability.  Post surgery, the updated medical record is posted to the athlete's Jamaican EMR system for follow-up medical treatment at home.

As a way to build an Olympic digital health ecosystem that includes all stakeholders willing to specify, prototype and deploy digital health technology, the OHI Foundation has been created as a not-for-profit, charitable organization.  The Foundation itself has no restriction on membership, and welcomes the participation and support of the global digital health community, namely vendors, healthcare providers, industry and standards organizations.

Recognized charter supporters, HIMSS and SNOMED International, lend their commitment to the pursuit of quality and safety improvements through health information technology and standards alike. Hal Wolfe, HIMSS CEO, states that "HIMSS is proud to sponsor the OHI Initiative as a representative of the digital health industry globally.  OHI supports an ecosystem at the Olympic Games that is built on the same standards, products and infrastructures that are being implemented around the world in order to deliver better health through information and technology. our industry is dedicated to the realization of that vision." Don Sweete, CEO, SNOMED International,  echoes that sentiment. "At the core of care delivery is the principle that clinicians can, beyond a shadow of a doubt, rely on available, accessible and unambiguous clinical information at any point of service. Demonstrating this critical relationship at work through OHI and in support of the healthcare program offered at each Olympic Games, we see a forward-looking example made possible by the interoperability of health information."

Michael Nusbaum, OHI's Executive Lead, has been a driving force in realizing the OHI vision. "Launching OHI through this year's HIMSS18 Interoperability Showcase speaks to the promise of global healthcare interoperability delivered through the lens of the Olympic Games, and for the benefit of participants, national teams, and host countries."

Interested parties can learn more about this initiative at a presentation and drinks reception Tuesday March 6, 4:30pm - 5:30pm  at the HIMSS Interoperability Showcase Theatre, and at an educational session Wednesday March 7th, 1:00pm - 2:00pm in Murano 3301.  Organizations and individuals interested in becoming an OHI Foundation partner are invited to visit the OHI kiosk at the Interoperability Showcase.

About OHI:
OHI, the Olympic Healthcare Interoperability Initiative, began early in 2017 to advance the seamless exchange and use of health information globally, leveraging the 2-year cadence of the Olympic Games and established international standards. Utilizing the latest innovations in digital health, OHI will connect pre-Games person-specific healthcare information with information generated at Games time by Olympic and Host City healthcare service providers: from athletes to staff/officials to volunteers to spectators.

The OHI Foundation is a not-for-profit, charitable organization based in the U.S. The Foundation provides the facilitation and management services required to progress its vision of advancing the use of digital health technology in conjunction with the Olympic Games to impact the health of individuals around the world. 

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0abf3f67-1fe7-43ac-ba17-1a58759b3431

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/49164c85-434e-4f60-bb85-d2ecdf2282de

Michael Nusbaum
Olympic Healthcare Interoperability Initiative 
+1 (250) 384-0001
michael@ohiinitiative.org



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Olympic Healthcare Interoperability Initiative via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development delays publication of its Annual Report for 2018 and changes date for the Annual General Meeting26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SWEDEN - 26 April 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that The Board of Directors has decided to delay the publication of its Annual Report for 2018. Karolinska Development has changed the date for the Annual General Meeting to June 26, 2019. The date for publication of the Annual Report for 2018 has been changed from April 26 to April 30, 2019. Karolinska Development has changed the date for the Annual General Meeting from June 4 to June 26, 2019. Notice to the Annual General Meeting will be published in a separate press release. For more information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, CFO, Karolinska Development AB Phone: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investmen

Karolinska Development senarelägger publicering av årsredovisningen för 2018 och meddelar nytt datum för årsstämma26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 26 april 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att styrelsen har beslutat att senarelägga publiceringen av årsredovisningen för 2018. Karolinska Development har ändrat datum för årsstämman till den 26 juni 2019. Publiceringen av årsredovisningen för 2018 flyttas från den 26 april till den 30 april 2019. Karolinska Development har ändrat datum för årsstämman från den 4 juni till den 26 juni 2019. Kallelse till årsstämman kommer att publiceras senare i ett separat pressmeddelande. För ytterligare information, vänligen kontakta: Viktor Drvota, vd, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, finanschef, Karolinska Development AB Tel: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TILL REDAKTÖRERNA Om Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) är ett nordiskt investmentbolag inom life science. Bolaget fokuserar p

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum